A possible breakthrough in the treatment of metastatic melanoma patients could be on the way. Around 290,000 people are diagnosed with the skin cancer every year.
The Danish cancer company IO Biotech has just entered into a partnership with the US pharmaceutical giant MSD. Together, they will develop a potential treatment against the serious cancer.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.